Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?

Would your answer change if it is bladder vs upper tract disease?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Do the results of IMvigor011 influence you to utilize ctDNA to guide all adjuvant IO in MIBC?

How do the results of KEYNOTE-B15/EV-304 influence your preferred treatment for cisplatin eligible MIBC?

What are your top takeaways from ASCO GU 2026?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.